Theranostic and nanotheranostic probes in nuclear medicine

Drude, Natascha; Tienken, Lena; Mottaghy, Felix M.

doi:10.1016/j.ymeth.2017.07.004

Cited by 42 publications

(33 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, antibody conjugates target the cell surface and tend to have limited access to solid tumors [ 96 ], whereas radiolabeled peptides are more desirable due to straightforward chemical synthesis, versatility, easier radiolabeling, optimum clearance from the circulation, faster penetration and more uniform distribution into tissues, and also lower immunogenicity [ 97 , 98 ]. Nanoparticle-based systems have been designed to improve biodistribution, stability, specificity, pharmacological and targeting properties, daughter retention, as well as to exploit the theranostic approach [ 99 , 100 , 101 ].…”

Section: Vectors For Targeted Alpha Particle Therapymentioning

confidence: 99%

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

2018

View full text Add to dashboard Cite

This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments.

show abstract

Section: Vectors For Targeted Alpha Particle Therapymentioning

confidence: 99%

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

2018

View full text Add to dashboard Cite

show abstract

“…This capacity promotes the use of AuCNs as efficient targeting system. In addition, the exhibition of fluorescence in a broad region (visible to near-infrared) makes AuNCs strong candidates to be used as imaging probes [7,12,15,20,21].…”

Section: Introductionmentioning

confidence: 99%

Radioactive gold nanocluster (198-AuNCs) showed inhibitory effects on cancer cells lines

Xuan

Silva

Nunes

et al. 2020

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Cancer is a global epidemic disease responsible for over ten millions death worldwide. The early diagnosis and the precise treatment with reduced adverse reactions are the main goal worldwide. In this study, we produced, characterized and evaluated (in vitro) in three different cancer cell lines (protaste, breast and melanoma) a radioactive gold nanocluster (R-AuNC) (198 Au25(Capt)18). The pharmacokinetics as the influence in the ABC transporter (MRP1 Efflux Transporter Protein) was also evaluated. The results showed that R-AuNC (198 Au25(Capt)18) are capable to kill the cancer cells lines of protaste, breast and melanoma. The pharmacokinetics showed a fast clearance and great volume of distribution, confirming the use of R-AuNC as nanomedicine for cancer treatment. Finally, the ABC transporter assay corroborated that the R-AuNC (198 Au25(Capt)18) has no risk of being pumped out of cells by this efflux transporter. The results validate the use of gold nanoparticles as therapeutic nanomedicine for cancer treatment.

show abstract

“…11,39–41 With advances made in unmasking biomarkers for disease states, another layer of complexity is currently being explored with nanotheranostics in which an additional targeting ligand (used for better accumulation at the target site) is added to the same physical entity. The goal of this study is to design a nanoparticle formulation that, as a single entity, will be able to target, carry payload, and monitor response to therapy.…”

Section: Discussionmentioning

confidence: 99%

Surface-Modified Shortwave-Infrared-Emitting Nanophotonic Reporters for Gene-Therapy Applications

Zhao

Kantamneni

et al. 2018

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Gene therapy is emerging as the next generation of therapeutic modality with United States Food and Drug Administration approved gene-engineered therapy for cancer and a rare eye-related disorder, but the challenge of real-time monitoring of on-target therapy response remains. In this study, we have designed a theranostic nanoparticle composed of shortwave-infrared-emitting rare-earth-doped nanoparticles (RENPs) capable of delivering genetic cargo and of real-time response monitoring. We showed that the cationic coating of RENPs with branched polyethylenimine (PEI) does not have a significant impact on cellular toxicity, which can be further reduced by selectively modifying the surface characteristics of the PEI coating using counter-ions and expanding their potential applications in photothermal therapy. We showed the tolerability and clearance of a bolus dose of RENPs@PEI in mice up to 7 days after particle injection in addition to the RENPs@PEI ability to distinctively discern lung tumor lesions in a breast cancer mouse model with an excellent signal-to-noise ratio. We also showed the availability of amine functional groups in the collapsed PEI chain conformation on RENPs, which facilitates the loading of genetic cargo that hybridizes with target gene in an in vitro cancer model. The real-time monitoring and delivery of gene therapy at on-target sites will enable the success of an increased number of gene- and cell-therapy products in clinical trials.

show abstract

Theranostic and nanotheranostic probes in nuclear medicine

Cited by 42 publications

References 77 publications

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

Radioactive gold nanocluster (198-AuNCs) showed inhibitory effects on cancer cells lines

Surface-Modified Shortwave-Infrared-Emitting Nanophotonic Reporters for Gene-Therapy Applications

Contact Info

Product

Resources

About